International Journal of Health and Allied Sciences


Background: Diabetes mellitus is one of the serious health concerns around the globe, characterized by hyperglycemia. It is also linked with several other disorders including neuropathy. One of the most typical diabetes-related comorbidities is depression. Objectives: In this investigation, euglycemic albino rats and streptozotocin-induced diabetic albino Wistar rats were used to assess the effects of fluoxetine, escitalopram, and fluvoxamine on blood glucose levels. Method: To measure euglycemic index, the three medications were given to several groups. After administering glucose, the blood glucose level was checked at 0, 60, and 150 minutes. Additionally, starting on the third day following the induction of diabetes, the test medications were given for a total of 28 days. The CBG (Capillary blood glucose) levels were assessed on days 0, 7, 14, 21, and 28 Results: According to the study, fluoxetine, escitalopram, and fluvoxamine have a hyperglycemic effect because the CBG values were significantly higher (p < 0.05) in the test groups at all time points in both euglycemic albino Wistar rats after glucose challenge and in rats with diabetes mellitus caused by streptozotocin. Conclusion: Based on the findings it can be suggested that the three anti-depressant drugs also possess hyperglycemic effects. The percentage of increase of CBG level was maximum with fluoxetine followed by fluvoxamine group and less with escitalopram at the all-time interval of OGTT. This indicates that the tendency of induction of hyperglycemia due to glucose challenge was more with fluoxetine & and fluvoxamine compared to escitalopram which may depict the relative safety of escitalopram as compared to fluoxetine & fluvoxamine as antidepressants in diabetic conditions. To ascertain this, further studies need to be performed to assess the mechanism of action of the drugs in bringing about hyperglycemic effects.